AGC Biologics’ Milan Cell and Gene Center will support commercial manufacturing of Waskyra, the ex vivo gene therapy developed by Fondazione Telethon for Wiskott-Aldrich syndrome, following market authorization by both the U.S. Food and Drug Administration and the European Commission.

What these dual approvals reveal about the future of ultra-rare gene therapy commercialization

The regulatory approvals of Waskyra in the United States and European Union represent more than just clinical validation of an ex vivo gene therapy for Wiskott-Aldrich syndrome. They offer a critical proof point for a nonprofit–CDMO collaboration model that challenges the traditional economic assumptions underpinning rare disease therapy manufacturing.

Fondazione Telethon, the Italian non-profit biomedical research foundation behind the gene therapy, has committed to bringing Waskyra to market despite the well-established barriers facing gene therapy developers in ultra-rare indications. With an estimated prevalence of one in 250,000 live male births, Wiskott-Aldrich syndrome remains a textbook example of a high-need, low-commercial-incentive indication. The disease results in immune dysfunction, thrombocytopenia, recurrent infections, and bleeding complications in early childhood—usually addressed through supportive care or hematopoietic stem cell transplantation when a matched donor is available.

Waskyra, by contrast, uses autologous CD34+ hematopoietic stem and progenitor cells transduced with a lentiviral vector carrying the therapeutic gene. The treatment offers a curative approach without relying on donor availability or immunological compatibility. While its clinical impact is significant, what sets this program apart is the path to commercialization—led not by a traditional biotech firm, but by a foundation with deep scientific and ethical roots, supported by AGC Biologics as its manufacturing and regulatory partner.

Why AGC Biologics’ Milan site is becoming a case study in ultra-rare therapy scale-up

AGC Biologics’ Milan Cell and Gene Center of Excellence has been instrumental in every phase of Waskyra’s development: from preclinical vector design and cell processing to clinical batch manufacturing, regulatory filings, and now commercial readiness. Industry observers note that this facility is increasingly being recognized as a global benchmark for delivering complex cell and gene therapies at commercial scale—particularly those that fall outside standard industry viability metrics.

The Milan site’s ability to navigate the regulatory, technical, and quality demands of such therapies positions it as a key player in an emerging trend: enabling niche therapies to scale despite cost and volume limitations. Waskyra is the third gene therapy manufactured at the site to receive full regulatory approval for a rare condition with minimal commercial upside. This portfolio includes therapies developed by nonprofit and academic sponsors who lack internal manufacturing capabilities but are unwilling to license or sell programs to commercial entities that may deprioritize launch based on return-on-investment calculations.

Scalability, typically a limiting factor for personalized or autologous therapies, was addressed through AGC Biologics’ established lentiviral vector production and patient-specific batch management infrastructure. While such manufacturing strategies are resource-intensive, the Milan site’s track record—hundreds of batches delivered, successful technology transfers, and compliance with evolving FDA and EMA guidelines—demonstrates that technical complexity does not need to be a dealbreaker for programs targeting fewer than a thousand patients globally.

What remains uncertain around long-term access, payer models, and clinician training

Even with regulatory green lights in hand, the road to routine clinical adoption of Waskyra is not without friction. Reimbursement models for gene therapies remain fragmented across regions, and payers are often reluctant to commit to high-cost interventions for ultra-rare diseases without long-term outcome data. Industry analysts tracking the gene therapy space suggest that non-profit developers like Fondazione Telethon may face additional scrutiny from health technology assessment (HTA) agencies due to perceived lack of commercial accountability mechanisms post-launch.

From a clinical standpoint, the delivery protocol for Waskyra—while standardized within academic centers—will likely require clinician training, specialized cell processing infrastructure, and a tightly coordinated patient journey across collection, vector transduction, and reinfusion. This represents a significant operational lift for community hospitals or regions without integrated advanced therapy centers.

Manufacturing consistency will also be under continued observation. Autologous therapies bring inherent batch-to-batch variability, and any changes to vector design, transduction efficiency, or cell viability must be tightly managed under post-approval change control frameworks. Regulatory watchers expect both the FDA and EMA to monitor real-world manufacturing and pharmacovigilance data closely during the early commercial rollout.

What this partnership model could unlock for future nonprofit-led gene therapy programs

Waskyra’s regulatory success may catalyze a broader rethinking of gene therapy commercialization models, particularly in the wake of high-profile program terminations due to cost or strategic reprioritization. In recent years, industry giants have shelved rare disease gene therapy programs citing unviable economics, limited market size, or manufacturing risk. In contrast, the Fondazione Telethon–AGC Biologics partnership demonstrates that alternative models—grounded in ethical access and long-term manufacturing collaboration—can succeed where purely profit-driven frameworks falter.

Clinicians familiar with the program believe this could encourage more academic institutions and patient advocacy groups to retain control over high-impact therapies, choosing experienced CDMO partners instead of out-licensing to commercial players. That said, questions remain about the scalability of this model beyond philanthropic ecosystems. Most nonprofit organizations lack the capital runway to support regulatory submissions, commercial manufacturing, and global distribution simultaneously—raising the possibility of hybrid structures involving public sector grants, multi-stakeholder pay-for-performance schemes, or pooled procurement initiatives for ultra-rare therapies.

Ultimately, Waskyra’s approval and AGC Biologics’ role in its development offer a glimpse into a future where the economics of manufacturing do not automatically determine access. But this future will depend on continued investment in adaptable GMP platforms, more transparent value frameworks for rare diseases, and regulatory support for non-traditional sponsors willing to lead.

Strategic takeaways from the Waskyra approvals and AGC Biologics’ role

The Waskyra case is likely to be closely watched by stakeholders across the gene therapy value chain—from CDMOs evaluating how to position their advanced therapy capabilities, to regulators assessing how to support novel sponsors, to clinicians and hospital networks preparing for procedural complexity. It also underscores a key industry inflection point: that the economics of rare disease gene therapy may not be as binary as once believed, especially when infrastructure, ethics, and mission align.

The question going forward is whether similar nonprofit-CDMO alliances can take root in other therapeutic areas—particularly those affecting even smaller populations or involving more complex delivery platforms. For now, AGC Biologics’ Milan site continues to serve as both a technical proving ground and a strategic blueprint for how to industrialize individualized care without compromising patient access or clinical integrity.

  AGC Biologics, cell and gene therapy, EMA, ex vivo gene therapy, FDA, Fondazione Telethon, lentiviral vector manufacturing, rare diseases, Waskyra, Wiskott-Aldrich syndrome